Currently, the Standard of Care that has been adopted for HCV management consists of the drug
‘pegylated interferon’, along with the drug ribavirin
The chances of eradicating the virus are dependent upon genotype. Typically, genotype 1 patients have a 45% chance of viral eradication; this requires treatment duration of 48 weeks minimum. For genotype 2 and 3 patients, the odds of clearing the virus increase to about 75-90%, with a treatment duration of 24 weeks, generally.